The median time from the last dose of abelacimab to the procedure was 29 days, with 55.8% of procedures occurring within the monthly dosing interval. Periprocedural bleeding—ISTH major/clinically ...

Milvexian is in three late-stage studies in AF, stroke, and acute coronary syndromes (ACS), while abelacimab is in the phase 3 LILAC-TIMI 76 in patients with AF deemed unsuitable for current OAC ...

Abelacimab is a fully human monoclonal antibody that binds to the catalytic domain of the inactive form of FXI and prevents the generation of the activated form (FXIa). 13 The AZALEA-TIMI 71 trial ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

In patients with atrial fibrillation (AFib) randomized to abelacimab vs. rivaroxaban, no statistically significant differences in bleeding risk were observed, suggesting that interruption of ...

The investigational antibody targets Factor XI, a key clotting protein. In 2019, Novartis helped launch Anthos alongside Blackstone Life Sciences, in the process offloading abelacimab to the startup.